Evidence Level:Sensitive: D – Preclinical
Title:
Antitumor activity of the investigational B7-H3 antibody-drug conjugate, vobramitamab duocarmazine, in preclinical models of neuroblastoma
Excerpt:Vobra duo treatment for 4 weeks further increased survival in both orthotopic and resected NB models….Vobra duo exerts relevant antitumor activity in preclinical B7-H3-expressing NB models…
DOI:10.1136/jitc-2023-007174